PixarBio Corporation expanded its regulatory team Monday with the addition of Steven Chartier as the vice president of the biotechnology company's regulatory affairs.
In his new role at PixarBio, Chartier will be responsible for overseeing all national and international regulatory issues, such as FDA filings of non-opiate drugs to treat neurological conditions.
"As we prepare for clinical studies for multiple pain indications, Steve will lead more than 20-plus applications to the U.S. FDA and to European bodies for pain, epilepsy and spinal cord injury products," PixarBio CEO Frank Reynolds said. "Steve will expand PixarBio Regulatory strategy to leverage our dominant patent position around the NeuroRelease platform."
Chartier, who obtained regulatory affairs certification from the Regulatory Affairs Professional Society, brings more than two decades of regulatory experience to the position at PixarBio, where he helped advance various novel therapeutics across numerous health areas including cardiovascular diseases and cancer. He most recently managed the regulatory, quality, manufacturing and clinical departments at cardiovascular imaging company Infraredx.
He also led preclinical development programs at Nucryst Pharmaceuticals as well as participated in program management and laboratory research at the Dana Farber Cancer Institute and Biogen IDEC.
Alerts Sign-up